论文部分内容阅读
目的观察阿德福韦酯片(商品名贺维力)联合双环醇片(商品名百赛诺)治疗慢性乙型肝炎(CHB)的临床疗效。方法将60例CHB患者按就诊顺序随机分为治疗组和对照组2组,每组各30例。治疗组患者每日口服贺维力10 mg(1次/d)、百赛诺25 mg(3次/d);对照组患者每日仅口服贺维力10 mg(1次/d);两组均连续用药48周。治疗前、治疗24周后、治疗48周后两组患者丙氨酸转氨酶(ALT)、尿素氮(BUN)、肌酐Cr水平比较采用t检验;治疗24周后、治疗48周后两组患者ALT复常率、HBV DNA转阴率比较采用χ2检验。结果治疗24周后治疗组患者ALT水平为(145.47±61.95)U/L,较对照组的(189.09±52.02)下降,且差异有统计学意义(t=2.953,P=0.005);同时治疗组ALT复常率高于对照组,差异也有统计学意义[80.0%(24/30)与43.3%(13/30)比较,χ2=7.051,P=0.008];但两组患者HBV DNA转阴率差异无统计学意义[50.0%(15/30)与43.3%(13/30)比较,χ2=0.067,P=0.796]。治疗48周后治疗组ALT水平低于对照组[(91.38±48.98)U/L与(60.03±29.89)U/L比较],而ALT复常率、HBV DNA转阴率均高于对照组[63.3%(19/30)与90.0%(27/30)比较,73.3%(22/30)与53.3%(16/30)比较],且差异均有统计学意义(t=2.515,P=0.015;χ2=4.565,P=0.033;χ2=4.800,P=0.029)。治疗24周后、治疗48周后两组患者肾功能指标(BUN、Cr水平)与治疗前比较均无明显改变,且差异均无统计学意义。两组患者在治疗过程中均未发现明显不良反应。结论贺维力联合百赛诺治疗CHB能取得更好的生化学应答和病毒学应答,且安全性好。
Objective To observe the clinical efficacy of adefovir dipivoxil (brand Hever force) combined with bicycloalcohol tablets (brand name Paclitaxel) in the treatment of chronic hepatitis B (CHB). Methods Sixty CHB patients were randomly divided into treatment group and control group according to the order of treatment. There were 30 patients in each group. Patients in the treatment group were orally administered with Heverin 10 mg once daily and Bai Sai Nuo 25 mg three times a day, while those in the control group were given Hever 10 mg once daily, 48 weeks. Before treatment and 24 weeks after treatment, the levels of ALT, BUN and creatinine Cr in two groups were compared by t-test after 48 weeks of treatment. After 24 weeks of treatment, ALT, Complex rate, HBV DNA negative rate using χ2 test. Results After treatment for 24 weeks, the level of ALT in the treatment group was (145.47 ± 61.95) U / L, which was significantly lower than that in the control group (189.09 ± 52.02) (t = 2.953, P = 0.005) ALT normalization rate was higher than the control group, the difference was statistically significant (80.0% (24/30) and 43.3% (13/30), χ2 = 7.051, P = 0.008]; but the two groups of patients with HBV DNA negative rate The difference was not statistically significant (50.0% (15/30) compared with 43.3% (13/30), χ2 = 0.067, P = 0.796]. After 48 weeks of treatment, the ALT level in the treatment group was lower than that in the control group [(91.38 ± 48.98) U / L and (60.03 ± 29.89) U / L], while the ALT normalization rate and the HBV DNA negative conversion rate were higher than those in the control group [ 63.3% (19/30) compared with 90.0% (27/30), 73.3% (22/30) and 53.3% (16/30)], and the differences were statistically significant (t = 2.515, P = ; χ2 = 4.565, P = 0.033; χ2 = 4.800, P = 0.029). After 24 weeks of treatment, the renal function indexes (BUN and Cr levels) of the two groups after 48 weeks of treatment did not change significantly compared with those before treatment, and the differences were not statistically significant. Two groups of patients in the course of treatment did not find any significant adverse reactions. Conclusion He Weili combined Bai Xianuo treatment of CHB can get better biochemical response and virological response, and good safety.